ClinicalTrials.gov
ClinicalTrials.gov Menu

Alcohol Interaction Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01181908
Recruitment Status : Completed
First Posted : August 13, 2010
Last Update Posted : June 27, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The purpose of this study is understand the effects of GSK114814 and alcohol in healthy volunteers when taken together.

Condition or disease Intervention/treatment Phase
Alcoholism Drug: single dose Phase 1

Detailed Description:
The primary objective of this study is to investigate the CNS effects of co-administration of GSK1144814 with alcohol. Healthy volunteers who meet the eligibility criteria will be randomized to receive GSK1144814 or placebo with alcohol.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Other
Official Title: A Study to Investigate the Psychomotor and Cognitive Effects of Alcohol When Co-administered With GSK1144814 or Matching Placebo in Healthy Subjects.
Actual Study Start Date : November 11, 2009
Actual Primary Completion Date : December 30, 2009
Actual Study Completion Date : December 30, 2009

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: GSK1144814
Subjects will receive either GSK1144814 or placebo at each treatment arm.
Drug: single dose
Subjects will receive a single dose of GSK1144814 or placebo.
Placebo Comparator: placebo
Subjects will receive either GSK1144814 or placebo at each treatment arm.
Drug: single dose
Subjects will receive a single dose of GSK1144814 or placebo.



Primary Outcome Measures :
  1. pharmacodynamic measures for various psychomotor/cognition function and subjective effects [ Time Frame: pre and post study drug administration ]

Secondary Outcome Measures :
  1. alcohol level [ Time Frame: during and post alcohol administration ]
  2. blood level of GSK1144814 [ Time Frame: pre and post study drug administration ]
  3. safety and tolerability as measured by adverse events, vital signs, clinical laboratory measurements and validated clinical assessment scales [ Time Frame: throughout the study pre- and post dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female
  • Body weight 50 kg or higher and BMI within the range 19 - 29.9 kg/m2
  • Willing to use appropriate contraception methods

Exclusion Criteria:

  • Positive HIV, Hepatitis B surface antigen or Hepatitis C antibody result
  • Any serious medical disorder or condition
  • Any history of an endocrine disorder.
  • Any clinically significant laboratory abnormality.
  • History of psychiatric illness.
  • Any history of suicidal attempts or behavior.
  • Positive urine drug screen or positive blood alcohol
  • Pregnant, nursing or potential to have a child
  • Past history of alcohol dependence or abuse.
  • History of increased sensitivity to the effects of alcohol or violent behaviour/aggression when intoxicated.
  • smokers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01181908


Locations
Netherlands
GSK Investigational Site
Leiden, Netherlands, 2333 CL
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Additional Information:
Publications:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01181908     History of Changes
Other Study ID Numbers: 113476
First Posted: August 13, 2010    Key Record Dates
Last Update Posted: June 27, 2017
Last Verified: June 2017

Keywords provided by GlaxoSmithKline:
alcohol
drug interaction
pharmacodynamic

Additional relevant MeSH terms:
Alcoholism
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Ethanol
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs